Investors
Where Innovation Meets Impact.
AI-Powered Platforms Transforming Digital Health and Driving Shareholder Value
Why Invest in AIML?
We are pioneering the future of health intelligence by developing and commercializing advanced AI-driven technologies that unlock powerful biometric insights
Backed by a growing portfolio of proprietary technologies and a world-class leadership team, AIML is committed to delivering long-term value to shareholders while improving health outcomes across global markets.
Press Releases
June 10, 2025
AIML Strengthens IP Portfolio with Provisional Patents for AI Driven ECG Signal Processing
Read More
June 3, 2025
AIML Subsidiary Neural Cloud Signs LOI with Circular Health to License MaxYield™ ECG Signal-Processing
Read More
May 22, 2025
AIML Establishes Innovation Committee, Appoints Dr. Drew Dundas as Chair
Read More
May 20, 2025
AIML Establishes Medical Advisory Board to Drive AI Powered ECG Signal Processing Innovation
Read More
May 15, 2025
AIML Hits Key Regulatory Benchmark with 510(k) Filing for MaxYield™ Signal Enhancement Platform
Read More
May 5, 2025
AIML Innovations Appoints Political Strategist and Public Affairs Leader, Michael Diamond, to Board of Directors
Read More
Press Releases Archive
Read more
Corporate Governance
Board of Directors
Financials
Read more on CSE
Read more
Charters & Policies
Company Structure
215.2
Million
Shares Outstanding
9.95
Million
Options
154.7
Million
Warrants Outstanding
379.8
Million
Fully Diluted